Huntsville, ALNCT07624305Now EnrollingIRB Ready

Renal Insufficiency, Chronic Clinical Trial in Huntsville, AL

Access cutting-edge renal insufficiency, chronic treatment through this phase 3 clinical trial at a research site in Huntsville. Study-provided care at no cost to qualified participants.

Sponsored by AstraZeneca

Quick Self-Assessment

See if you qualify for this Huntsville location

Preparing your pre-screening questions…

Expert Care in Huntsville

Access renal insufficiency, chronic specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related renal insufficiency, chronic treatment provided free

Apply for This Huntsville Location

Check if you qualify for this renal insufficiency, chronic clinical trial in Huntsville, AL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Huntsville

    Convenient for AL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Huntsville site if eligible
  4. 4Begin participation

About This Renal Insufficiency, Chronic Study in Huntsville

The purpose of this study is to evaluate the efficacy, safety and tolerability of balcinrenone in fixed combination with dapagliflozin, compared with dapagliflozin, in patients with CKD Stage 3b and 4 (eGFR ≥ 15 to \< 45 mL/min/1.73 m2) administered orally once daily in addition to SoC. This is a population with high unmet medical need and an increased risk of CKD progression, who are frequently excluded from interventional trials.

Sponsor: AstraZeneca

Who Can Participate

Inclusion Criteria

Age ≥ 18 years
Diagnosis of CKD and at least one of the following:
eGFR ≥ 15 to \< 45 mL/min/1.73 m2 AND: UACR ≥ 30 mg/g (central laboratory) or UACR ≥ 100 mg/g (local laboratory ) or UPCR ≥ 200 mg/g (local laboratory).
eGFR ≥ 15 to \< 30 mL/min/1.73 m2 and UACR \< 30 mg/g (local or central laboratory UACR value).
Serum/plasma K+ ≤ 5.0 mmol/L
Maximum tolerated dose of an ACEi or an ARB, unless contraindicated or not tolerated. The dose should be stable for at least 4 weeks before screening.

Exclusion Criteria

Recent (within 90 days prior to screening) or ongoing dialysis, or likely to require dialysis within 3 months following randomisation
UACR ≥ 5000 mg/g or UPCR ≥ 7000 mg/g at screening.
SBP \> 180 mmHg or DBP \> 110 mmHg at screening.
SBP \< 90 mmHg at screening.
HbA1c \> 9% at screening
T1DM, except:
For US only: patients with T1DM treated with SGLT2i for at least 4 months prior to screening, without DKA during that period, and who have experience with ketone monitoring are eligible.
For Japan only: patients with T1DM treated with dapagliflozin 10 mg for at least 4 months prior to Screening, without DKA during the period of dapagliflozin treatment are eligible for inclusion.
Autosomal dominant polycystic kidney disease.
Major cardiac or valvular surgery, acute coronary syndrome (myocardial infarction or unstable angina), stroke, transient ischaemic attack within 12 weeks prior to screening.
Severe hepatic impairment (Child-Pugh Class C).
Adrenal insufficiency.
Clinically significant acute kidney injury within 12 weeks prior to the screening.
New York Heart Association functional HF class IV at screening, or hospitalisation for heart failure within 4 weeks prior to screening.
Any clinical condition requiring systemic immunosuppression therapy other than maintenance therapy (stable for at least 3 months) prior to screening.
Solid organ or bone marrow transplant or a plan for transplant within 6 months following randomisation.
Any use of the following medications and supplements:
Aldosterone analogues
Aldosterone synthase inhibitors
Any use of potassium binders within 2 weeks prior to screening. Use is allowed after randomisation.
Strong or moderate inducers or inhibitors of CYP3A4, prohibited at least one week prior to randomisation

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Huntsville?

Yes, this clinical trial (NCT07624305) has an active research site in Huntsville, AL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Renal Insufficiency, Chronic Treatment Options in Huntsville, AL

If you're searching for renal insufficiency, chronic treatment options in Huntsville, AL, this clinical trial (NCT07624305) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Huntsville research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced renal insufficiency, chronic specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all renal insufficiency, chronic clinical trials near you to find additional studies recruiting in your area.

More Interstitial Cystitis Trials in Huntsville, AL

See all interstitial cystitis clinical trials recruiting in Huntsville — not just this study.

Browse Interstitial Cystitis Trials in Huntsville →

Browse More Trials by Condition

Interstitial Cystitis TrialsAll Conditions →

Ready to Join in Huntsville?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Huntsville, AL